Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore.
Duke-NUS Medical School, Singapore, Singapore.
Ann Nucl Med. 2021 May;35(5):557-568. doi: 10.1007/s12149-021-01598-4. Epub 2021 Mar 8.
Natural killer T-cell lymphoma (NKTCL) is an aggressive type of non-Hodgkin's lymphoma. While FDG-PET/CT imaging has been increasingly utilized for disease assessment, its prognostic value and potential utility in NKTCL patient stratification remain controversial. We aim to investigate the prognostic utility of FDG-PET/CT and its role in complementing clinical indices.
We conducted a retrospective review of 72 patients from a tertiary National Cancer Centre with biopsy-proven NKTCL and available FDG-PET/CT data (either baseline, end of treatment or both). Survival analysis was performed using the Kaplan-Meier method and multivariable Cox proportional regression.
High initial SUVmax was significantly associated with advanced Ann-Arbor stage (p = 0.0352), elevated LDH levels (p = 0.0059) and plasma EBV DNA detection (p = 0.0278). SUVmax correlated with worse progression-free survival (PFS) (HR 3.68, 95% CI 1.56-8.69, p = 0.0030) and a trend toward worse overall survival (OS) (HR 2.06, 95% CI 0.95-4.45, p = 0.0676). End of treatment Deauville scores of 4-5, as compared to scores of 1-3, was associated with worse PFS (HR 2.72, 95% CI 1.04-7.12, p = 0.0419). Notably, while all patients with scores of 5 developed progressive disease, only 2 of 5 patients with scores of 4 eventually relapsed. Clinical indices (NABS score) were still able to stratify survival outcomes regardless of end-of-treatment Deauville scores.
A Deauville score of 5 is more diagnostic of true disease progression than a score of 4, and NABS score may be used in patients who achieve Deauville scores of 1-3 for further risk stratification. A higher SUVmax at baseline portends a worse prognosis in NKTCL.
自然杀伤 T 细胞淋巴瘤(NKTCL)是一种侵袭性非霍奇金淋巴瘤。虽然 FDG-PET/CT 成像已越来越多地用于疾病评估,但它在 NKTCL 患者分层中的预后价值和潜在用途仍存在争议。我们旨在研究 FDG-PET/CT 的预后价值及其在补充临床指标方面的作用。
我们对来自一家三级国家癌症中心的 72 名经活检证实的 NKTCL 患者进行了回顾性研究,这些患者均有 FDG-PET/CT 数据(基线、治疗结束或两者均有)。使用 Kaplan-Meier 方法和多变量 Cox 比例风险回归进行生存分析。
初始 SUVmax 较高与较晚期的 Ann-Arbor 分期(p=0.0352)、较高的 LDH 水平(p=0.0059)和血浆 EBV DNA 检测(p=0.0278)显著相关。SUVmax 与无进展生存期(PFS)较差相关(HR 3.68,95%CI 1.56-8.69,p=0.0030),且与总生存期(OS)较差呈趋势相关(HR 2.06,95%CI 0.95-4.45,p=0.0676)。与 1-3 分相比,治疗结束时的 Deauville 评分 4-5 与较差的 PFS 相关(HR 2.72,95%CI 1.04-7.12,p=0.0419)。值得注意的是,虽然所有评分 5 的患者均发生进行性疾病,但仅 2 例评分 4 的患者最终复发。无论治疗结束时的 Deauville 评分如何,临床指标(NABS 评分)仍能够分层生存结局。
Deauville 评分 5 比评分 4 更能诊断真正的疾病进展,而 NABS 评分可用于获得 Deauville 评分 1-3 的患者进行进一步的风险分层。基线时 SUVmax 较高预示着 NKTCL 的预后较差。